Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥ 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial

<p>Abstract</p> <p>Background</p> <p>Postmenopausal women are prone to develop functional disabilities as a result of reduction in muscle strength and muscle mass caused by diminished levels of female sex hormones. While hormone replacement therapy may counteract these...

Full description

Bibliographic Details
Main Authors: Grobbee Diederick E, Schouw Yvonne, Samson Monique M, Jacobsen Didy E, Verhaar Harald JJ
Format: Article
Language:English
Published: BMC 2008-06-01
Series:Trials
Online Access:http://www.trialsjournal.com/content/9/1/32
_version_ 1818956530699993088
author Grobbee Diederick E
Schouw Yvonne
Samson Monique M
Jacobsen Didy E
Verhaar Harald JJ
author_facet Grobbee Diederick E
Schouw Yvonne
Samson Monique M
Jacobsen Didy E
Verhaar Harald JJ
author_sort Grobbee Diederick E
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Postmenopausal women are prone to develop functional disabilities as a result of reduction in muscle strength and muscle mass caused by diminished levels of female sex hormones. While hormone replacement therapy may counteract these changes, conventional hormone replacement therapy is associated with potential harmful effects, such as an increased risk of breast cancer, and its prescription is not recommended. For this reason newer alternative drugs, such as tibolone, a synthetic steroid with estrogenic, progestogenic and androgenic activity, and raloxifene, a selective estrogen receptor modulator, may be more appropriate. This trial investigates the effect of tibolone and raloxifene on muscle strength.</p> <p>Methods</p> <p>We recruited 318 elderly women in our single-center randomized, double-blind, double-dummy, placebo-controlled trial. Participants were randomized to tibolone 1.25 mg (Org OD 14, Organon NV, the Netherlands) plus placebo, raloxifene 60 mg (Evista<sup>®</sup>, Eli Lilly, United States) plus placebo or two placebo tablets daily for 24 months.</p> <p>The primary aim is to determine if there is a difference between tibolone and placebo or if there is a difference between raloxifene and placebo. Primary endpoints are muscle strength and bone mineral density. The secondary endpoints are postural balance, body composition, cognitive function, anxiety, mood and quality of life. The secondary aim is to determine if there is a difference between tibolone and raloxifene.</p> <p>The measure of effect is the change from the baseline visit to the visits after 3 months, 6 months, 12 months, and 24 months. A follow-up measurement is planned at 30 months to determine whether any effects are sustained after cessation of the study. By December 2007 the blind will be broken and the data analyzed.</p> <p>Trial registration number</p> <p>NTR: 1232</p>
first_indexed 2024-12-20T10:55:25Z
format Article
id doaj.art-9710d14ac07e47d996472acc601401da
institution Directory Open Access Journal
issn 1745-6215
language English
last_indexed 2024-12-20T10:55:25Z
publishDate 2008-06-01
publisher BMC
record_format Article
series Trials
spelling doaj.art-9710d14ac07e47d996472acc601401da2022-12-21T19:43:09ZengBMCTrials1745-62152008-06-01913210.1186/1745-6215-9-32Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥ 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trialGrobbee Diederick ESchouw YvonneSamson Monique MJacobsen Didy EVerhaar Harald JJ<p>Abstract</p> <p>Background</p> <p>Postmenopausal women are prone to develop functional disabilities as a result of reduction in muscle strength and muscle mass caused by diminished levels of female sex hormones. While hormone replacement therapy may counteract these changes, conventional hormone replacement therapy is associated with potential harmful effects, such as an increased risk of breast cancer, and its prescription is not recommended. For this reason newer alternative drugs, such as tibolone, a synthetic steroid with estrogenic, progestogenic and androgenic activity, and raloxifene, a selective estrogen receptor modulator, may be more appropriate. This trial investigates the effect of tibolone and raloxifene on muscle strength.</p> <p>Methods</p> <p>We recruited 318 elderly women in our single-center randomized, double-blind, double-dummy, placebo-controlled trial. Participants were randomized to tibolone 1.25 mg (Org OD 14, Organon NV, the Netherlands) plus placebo, raloxifene 60 mg (Evista<sup>®</sup>, Eli Lilly, United States) plus placebo or two placebo tablets daily for 24 months.</p> <p>The primary aim is to determine if there is a difference between tibolone and placebo or if there is a difference between raloxifene and placebo. Primary endpoints are muscle strength and bone mineral density. The secondary endpoints are postural balance, body composition, cognitive function, anxiety, mood and quality of life. The secondary aim is to determine if there is a difference between tibolone and raloxifene.</p> <p>The measure of effect is the change from the baseline visit to the visits after 3 months, 6 months, 12 months, and 24 months. A follow-up measurement is planned at 30 months to determine whether any effects are sustained after cessation of the study. By December 2007 the blind will be broken and the data analyzed.</p> <p>Trial registration number</p> <p>NTR: 1232</p>http://www.trialsjournal.com/content/9/1/32
spellingShingle Grobbee Diederick E
Schouw Yvonne
Samson Monique M
Jacobsen Didy E
Verhaar Harald JJ
Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥ 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial
Trials
title Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥ 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial
title_full Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥ 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial
title_fullStr Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥ 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial
title_full_unstemmed Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥ 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial
title_short Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥ 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial
title_sort efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength bone mineral density balance body composition cognitive function mood depression anxiety and quality of life well being in late postmenopausal women ≥ 70 years study design of a randomized double blind double dummy placebo controlled single center trial
url http://www.trialsjournal.com/content/9/1/32
work_keys_str_mv AT grobbeediedericke efficacyoftiboloneandraloxifeneforthemaintenanceofskeletalmusclestrengthbonemineraldensitybalancebodycompositioncognitivefunctionmooddepressionanxietyandqualityoflifewellbeinginlatepostmenopausalwomen70yearsstudydesignofarandomizeddoubleblinddoubledummypl
AT schouwyvonne efficacyoftiboloneandraloxifeneforthemaintenanceofskeletalmusclestrengthbonemineraldensitybalancebodycompositioncognitivefunctionmooddepressionanxietyandqualityoflifewellbeinginlatepostmenopausalwomen70yearsstudydesignofarandomizeddoubleblinddoubledummypl
AT samsonmoniquem efficacyoftiboloneandraloxifeneforthemaintenanceofskeletalmusclestrengthbonemineraldensitybalancebodycompositioncognitivefunctionmooddepressionanxietyandqualityoflifewellbeinginlatepostmenopausalwomen70yearsstudydesignofarandomizeddoubleblinddoubledummypl
AT jacobsendidye efficacyoftiboloneandraloxifeneforthemaintenanceofskeletalmusclestrengthbonemineraldensitybalancebodycompositioncognitivefunctionmooddepressionanxietyandqualityoflifewellbeinginlatepostmenopausalwomen70yearsstudydesignofarandomizeddoubleblinddoubledummypl
AT verhaarharaldjj efficacyoftiboloneandraloxifeneforthemaintenanceofskeletalmusclestrengthbonemineraldensitybalancebodycompositioncognitivefunctionmooddepressionanxietyandqualityoflifewellbeinginlatepostmenopausalwomen70yearsstudydesignofarandomizeddoubleblinddoubledummypl